血管免疫母细胞性T细胞淋巴瘤治疗研究进展

The status of treatment study in angioimmunoblastic T-cell lymphoma

血管免疫母细胞性T细胞淋巴瘤（AITL）是一种系统性、侵袭性外周T细胞淋巴瘤，目前仍然缺乏标准治疗方案。联合化疗没有明显改善预后且缓解持续时间短；靶向药物和免疫抑制治疗研究样本小，不能明确疗效；大剂量化疗联合自体造血干细胞移植（HDT—ASCT）和异基因造血干细胞移植（allo-HSCT）虽然都取得了显著疗效，但HDT—ASCT具有高复发率、远期继发肿瘤等诸多风险，allo—HSCT亦因移植相关死亡率较高而有待进一步探讨。文章就近年来AITL的治疗研究进展加以综述。

Angioimmunoblastic T-cell lymphoma（AITL） is a subtype of peripheral T-cell lymphoma, clinically characterized with systemic symptoms and aggressive behaviours. To date, the standard approach for treating patients with AITL is still unknown. Combination chemotherapy regimens have failed to significantly improve prognosis and durably maintain the remission. Targeted drugs and immunomodulator agents could not conclude the role because of the small number of patients in these studies. High dose therapy with autologous stem cell transplantation and allogeneic hematologic stem cell transplantation are both comparatively efficient. High dose therapy with autologous stem cell transplantation has many risks, such as higher relapse rate and long-term secondary tumor. Owing to higher transplant related mortality , allogeneic hematologic stem cell transplantation will be further explored. This review presents the status of treatment study in AITL.